# Apellis Pharmaceuticals, Inc. clinical trials: 28 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials with Apellis Pharmaceuticals, Inc. as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Apellis Pharmaceuticals, Inc.: 28 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/apellis-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 10, 2025 | NCT07215390 | A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics... | Apellis Pharmaceuticals, Inc. | Phase 2 | Recruiting | Geographic Atrophy Secondary to Age-related Macular Degeneration | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07215390) |
| October 9, 2025 | NCT07214740 | Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe | Apellis Pharmaceuticals, Inc. | Phase 3 | Completed | Geographic Atrophy Secondary to Age-related Macular Degeneration | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214740) |
| October 9, 2025 | NCT07213960 | A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis | Apellis Pharmaceuticals, Inc. | Phase 2/3 | Recruiting | FSGS | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213960) |
| June 13, 2025 | NCT07020832 | Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney... | Apellis Pharmaceuticals, Inc. | Phase 3 | Withdrawn | Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020832) |
| July 12, 2024 | NCT06499571 | Geographic Atrophy Long-Terms Outcomes Study | Apellis Pharmaceuticals, Inc. | Observational | Completed | Geographic Atrophy | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06499571) |
| December 8, 2023 | NCT06161584 | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of... | Apellis Pharmaceuticals, Inc. | Observational | Active not recruiting | Geographic Atrophy | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06161584) |
| April 12, 2023 | NCT05809531 | An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants... | Apellis Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G)... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05809531) |
| October 5, 2021 | NCT05067127 | Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex... | Apellis Pharmaceuticals, Inc. | Phase 3 | Completed | C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G)... | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05067127) |
| May 26, 2021 | NCT04901936 | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Apellis Pharmaceuticals, Inc. | Phase 2 | Recruiting | Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04901936) |
| February 25, 2021 | NCT04770545 | An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to... | Apellis Pharmaceuticals, Inc. | Phase 3 | Completed | Geographic Atrophy Secondary to Age-related Macular Degeneration | 792 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04770545) |
| January 28, 2021 | NCT04729062 | C3G/Primary IC-MPGN EAP | Apellis Pharmaceuticals, Inc. | Not applicable | Approved for marketing | C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G)... | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04729062) |
| October 8, 2020 | NCT04579666 | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) | Apellis Pharmaceuticals, Inc. | Phase 2 | Terminated | Amyotrophic Lateral Sclerosis, Motor Neuron Disease | 249 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04579666) |
| October 1, 2020 | NCT04572854 | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | Apellis Pharmaceuticals, Inc. | Phase 2 | Completed | C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease... | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04572854) |
| May 26, 2020 | NCT04402060 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | Apellis Pharmaceuticals, Inc. | Phase 1/2 | Completed | COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory... | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04402060) |
| September 11, 2019 | NCT04085601 | A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH | Apellis Pharmaceuticals, Inc. | Phase 3 | Completed | Paroxysmal Nocturnal Hemoglobinuria | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04085601) |
| December 17, 2018 | NCT03777332 | Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy | Apellis Pharmaceuticals, Inc. | Phase 1 | Completed | Geographic Atrophy | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03777332) |
| July 20, 2018 | NCT03593200 | A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects... | Apellis Pharmaceuticals, Inc. | Phase 2 | Completed | PNH | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03593200) |
| May 21, 2018 | NCT03531255 | Pegcetacoplan Long Term Safety and Efficacy Extension Study | Apellis Pharmaceuticals, Inc. | Phase 3 | Completed | PNH | 137 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03531255) |
| May 15, 2018 | NCT03525613 | A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA)... | Apellis Pharmaceuticals, Inc. | Phase 3 | Completed | Geographic Atrophy | 637 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03525613) |
| May 15, 2018 | NCT03525600 | Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA)... | Apellis Pharmaceuticals, Inc. | Phase 3 | Completed | Geographic Atrophy | 621 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03525600) |
| April 18, 2018 | NCT03500549 | Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Apellis Pharmaceuticals, Inc. | Phase 3 | Completed | Paroxysmal Nocturnal Hemoglobinuria | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03500549) |
| March 14, 2018 | NCT03465709 | Pegcetacoplan (APL-2) in Neovascular AMD | Apellis Pharmaceuticals, Inc. | Phase 1/2 | Terminated | Neovascular Age-related Macular Degeneration | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03465709) |
| March 5, 2018 | NCT03453619 | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | Apellis Pharmaceuticals, Inc. | Phase 2 | Completed | IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03453619) |
| July 24, 2017 | NCT03226678 | Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold... | Apellis Pharmaceuticals, Inc. | Phase 2 | Completed | Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03226678) |
| October 28, 2015 | NCT02588833 | Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. | Apellis Pharmaceuticals, Inc. | Phase 1 | Completed | Paroxysmal Nocturnal Hemoglobinuria | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02588833) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 2 |
| Phase 2 | 8 |
| Phase 2/3 | 1 |
| Phase 3 | 10 |
| Not applicable | 1 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Recruiting | 3 |
| Active not recruiting | 2 |
| Terminated | 2 |
| Approved for marketing | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Geographic Atrophy | 7 |
| Hemoglobinuria, Paroxysmal | 6 |
| Glomerulonephritis, Membranoproliferative | 5 |
| Anemia | 3 |
| Hemoglobinuria | 3 |
| Hemolysis | 3 |
| Hematologic Diseases | 3 |
| Anemia, Hemolytic, Autoimmune | 1 |
| Glomerulonephritis, IGA | 1 |
| Lupus Nephritis | 1 |
| Glomerulonephritis, Membranous | 1 |
| Amyotrophic Lateral Sclerosis | 1 |
| Motor Neuron Disease | 1 |
| Macular Degeneration | 1 |
| COVID-19 | 1 |
| Coronavirus Infections | 1 |
| Severe Acute Respiratory Syndrome | 1 |
| Acute Lung Injury | 1 |
| Respiratory Distress Syndrome | 1 |
| Anemia, Hemolytic | 1 |
| Delayed Graft Function | 1 |
| Kidney Failure, Chronic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Syrian restaurants in the United States](https://specstream.ai/data/businesses/syrian-restaurants/united-states)
- [Building contractors in the United States](https://specstream.ai/data/businesses/building-contractors/united-states)
- [Greek restaurants in the United States](https://specstream.ai/data/businesses/greek-restaurants/united-states)
- [Physical therapy clinics in the United States](https://specstream.ai/data/businesses/physical-therapy-clinics/united-states)
- [Window installers in the United States](https://specstream.ai/data/businesses/window-installers/united-states)
